O
besity is now pandemic in the United States and other industrialized countries (FIGURE 1), [1] [2] [3] the result by and large of a combination of inappropriate diets and inadequate exercise. And the problem is no longer confined to industrialized countries. Rapid Westernization of diet and lifestyle among urban dwellers in India, China, and elsewhere has been followed by an alarming rise in obesity-related health problems. 4, 5 The morbidly obese patient presents a particular challenge because of the massive weight loss that needs to be achieved. It was for this patient that bariatric surgery was first proposed in the 1950s, leading to emergence of a surgical specialty that last year performed more than 140,000 operations in the United States. As Henry Buchwald will discuss in the next article, the safety and efficacy of bariatric surgical techniques have improved over the years and a substantial body of evidence has been accumulated.
The clinician often is reluctant to consider bariatric surgery as an option even though nonsurgical treatments for severe obesity remain far from ideal. When all available options for managing morbid obesity are compared, it is difficult to dismiss operative therapy as a viable consideration.
Startling statistics
Obesity is defined as a body mass index (BMI) greater than 30 kg/m 2 are considered to be extremely or morbidly obese (class III obesity), as are those with BMIs greater than 37 kg/m 2 and obesityrelated comorbidity. 6 Although other measures of obesity are available, BMI is easily determined; moreover, it is used as the standard for weight determination in the majority of clinical studies of obesity. 7 On basis of these BMI criteria, approximately 65% of adults in the United States are overweight, and 31%-an 8% increase in 1 decade-are obese. 1 More than 15% of adolescents are overweight, up from about 5% in the early 1970s (FIGURE 2). 7 In the last 10 to 15 years, the average BMI of the US population has increased from 24.9 to 26.5 kg/m 2 . 8 The prevalence of class III obesity rose even faster-today, an estimated 2.2% to 4.7% of Americans are morbidly obese. 1, 2, 8 The prevalence is particularly high among US women, 6 .3% of whom are now morbidly obese, while among non-Hispanic black women the rate is now 15%. 1 Using data from the Behavioral Risk Factor Surveillance System, Sturm calculated that the prevalence of BMIs of 40 kg/m 2 and higher quadrupled between 1986 and 2000, while the prevalence of BMIs of 50 kg/m 2 and higher-the heaviest Americans-increased by a factor of 5.
400,000 deaths in the United States were attributable to poor diet and lack of regular physical activity. 15 In addition, loss of normal life expectancy for 25-year-olds with class III obesity is estimated to be as much as 20 years for black men, 13 years for white men, 5 years for black women, and 8 years for white women. 16 Whether obesity contributes directly to mortality independently of poor diet and sedentary lifestyle remains controversial. 17 Moreover, there is disagreement about the effect of weight loss on mortality because of the difficulty in separating intentional weight loss from disease-related weight loss. In a recent prospective study, Gregg et al concluded that intentional weight loss is associated with a 24% reduction (relative risk, 0.76; 95% CI, 0.60-0.97) in mortality. 18 
Diabetes
Type 2 diabetes mellitus is clearly linked to obesity. The estimated 10-year odds ratio for the development of type 2 diabetes is 17 in men and women with BMIs greater than 30 kg/m 2 . For patients with BMIs greater than 35 kg/m 2 , the odds ratio increases to 34 in women and 41 in men. 10 Approximately 11% of men and 20% of women with class III obesity also have type 2 diabetes. 10 Multiple studies involving men, women, and various ethnic groups have confirmed an association between morbid obesity and type 2 diabetes. 10, 11, 19 The effect of weight loss on type 2 diabetes can be significant. For example, Anderson and Konz reported that for every 5-kg weight loss, the average fasting glucose level decreased by 18 mg/dL. 12 In particular, bariatric surgery is associated with dramatic and prolonged improvement in blood glucose control. Blood glucose values are normalized in 77% to 86% of patients with type 2 diabetes who undergo surgery for morbid obesity. [20] [21] [22] [23] 
Coronary artery disease
Obesity has been identified as an independent risk factor for the development of coronary artery disease (CAD) in both men and women. The magnitude of the risk is similar to that of other coronary risk factors, including hyperlipidemia, hypertension, and cigarette smoking. 12, 24 The relative risk for the development of CAD in patients with BMIs greater than 30 kg/m 2 is approximately 1.6 times that of their normal-weight counterparts, even after adjusting for other CAD risk factors. 11, 24, 25 In morbidly obese patients, the relative risk of CAD is approximately 1.7 to 2.2 times greater than In 1991, the highest obesity (BMI ≥30 kg/m 2 ) prevalence rate by state among US adults was 15% to 19%, and it was documented in only 4 states. In 2003, this prevalence rate was noted in 15 states; moreover, 31 states had rates of 20% to 24%, and 4 states had rates of more than 25%. Adapted from Behavioral Risk Factor Surveillance System (BRFSS), Centers for Disease Control and Prevention, and Mokdad et al. 2 
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in their normal-weight counterparts. 10, 11 It has been calculated that for every kilogram of weight gained after high school, the risk of CAD increases by 5.7% in women and by 3.1% in men. 12 Data on the effects of bariatric surgery on the onset or progression of CAD are lacking, and prospective cohort studies have failed to demonstrate a reduction in cardiovascular mortality when intentional weight loss is achieved nonsurgically. 26 
Hypertension
Men with class III obesity are 1.7 to 4.6 times more likely to have hypertension than matched normal-weight controls. In morbidly obese women, the risk increases by a factor of 1.4 to 5.5.
2,10
As with diabetes, weight loss ameliorates hypertension. In obese patients, every 1-kg decrease in body weight is accompanied by an average decrease of 0.6 mm Hg in systolic blood pressure and 0.34 mm Hg in diastolic pressure. 12 The beneficial effect of weight loss on blood pressure is consistently seen when weight loss is achieved through lifestyle modification; 27 however, it may not occur when weight loss is achieved with appetite-suppressing drugs. 6, 12, 28, 29 Bariatric surgery is associated with complete resolution of hypertension in 60% to 70% of patients with morbid obesity.
22,30

Arthritis
The risk of osteoarthritis, predominantly in the weightbearing joints, is increased in all obese patients. 11, 31 In patients with class III obesity, the relative risk for osteoarthritis is 10. 11 The knee joint is particularly vulnerable-for every 5-unit increase in BMI, the relative risk for bilateral knee arthritis increases by 2.6. 31 An increasing prevalence of hip arthritis also has been correlated directly with increasing BMI.
Total knee and hip arthroplasty rates are strongly associated with progressive obesity. In morbidly obese men, the odds ratios of total knee and hip arthroplasty are 16 and 9, respectively. 32 Morbidly obese women are 19 times more likely to undergo knee replacement than normal-weight controls. 32 In patients with established arthritis, weight loss is associated with decreased pain and increased function. 33 Weight loss also has been associated with decreased progression of knee arthritis, 34 but not of hip arthritis. 35 Joint pain is alleviated after bariatric surgery, and surgical patients also are more likely to be physically active than their nonsurgical counterparts.
36,37
Cancer
Observational studies have noted that elevated BMIs were associated with increasing risk of several cancers, including but not limited to, cancer of the breast, colon, prostate, ovaries, and uterus (FIGURE 3). 10, 38 Although precise mechanisms have not been elucidated, a likely hypothesis is that accumulating adipose tissue affects circulating levels of tumor-promoting peptides and steroid hormones. 39 The relative risk of colon cancer in patients with BMIs greater than 35 kg/m 2 is 1.8 to 2.2. 9, 38 As is seen with other obesity related conditions, increasing obesity escalates the risk of cancer. Studies of women have shown that intentional weight loss was associated with a reduced
Prevalence of overweight among US children and adolescents
From 1977 to 2000, the prevalence of overweight (95% of BMI for age) increased 5% among children aged 2 to 5 years, 11% among children aged 6 to 11 years, and 10% among adolescents (12-19 yr chosocial complications that can be attributed to their weight. In particular, morbidly obese patients report impaired mobility, reduced energy levels, a high degree of emotional distress, and impaired psychosocial functioning (eg, social isolation, feelings of failure and hopelessness). 43, 44 Psychosocial complications are reinforced by social, educational, and workplace stigmatization-potential partners, teachers, school administrators, employers, and even physicians and other health professionals tend to rate obese individuals unfavorably compared with individuals of normal weight. 44, 45 Several studies have used validated survey instruments to demonstrate that the quality of life decreases as BMI increases and that as weight is lost, patients report improved quality of life. [44] [45] [46] Nonsurgical treatment Nonsurgical treatment for extremely obese patients includes lifestyle changes (eg, diet and exercise), pharmacologic therapy, alternative drug therapies and tech- incidence of all cancers, as well as breast and colon cancer. 40, 41 These studies did not specify the methods of weight loss, and it has yet to be determined whether surgically induced weight loss reduces cancer risk.
The high cost of obesity
About $50 billion annually are spent on direct care of obesity-related complications and another $30 billion are spent on weight-loss products and programs. 6 This sum accounts for nearly 5% of all medical costs in the United States. 6 In addition to the cost of treating associated medical conditions, obese patients are less productive and more prone to disability. 42 Thus, strategies aimed at reducing the burden of obesity are likely to have a major impact on the US health care system and society as a whole. sibutramine and orlistat, have been approved for longterm use. The US Food and Drug Administration includes the proviso that these 2 agents be administered in conjunction with a reduced-calorie diet.
Sibutramine suppresses appetite through its inhibition of norepinephrine, serotonin, and dopamine reuptake. In clinical studies, patients taking sibutramine had a weight loss that was about 4 to 5 kg greater than that in placebo patients after 1 year of treatment. 28, 29, 47, 49 Even more significant, these studies excluded patients with BMIs greater than 40 kg/m 2 . Indeed, no studies of the efficacy of sibutramine in morbidly obese patients have been completed.
Attrition rates in sibutramine trials have ranged from 17% to 47%. The most common side effects were dry mouth, anorexia, insomnia, constipation, and headache. 28, 29, 49 The agent also has been associated with small elevations of blood pressure and heart rate and should be administered with caution in patients with hypertension, particularly when it is uncontrolled or poorly controlled.
Orlistat is a lipase inhibitor that prevents absorption of dietary fats in the stomach and small intestine. A Cochrane review of 11 orlistat trials indicated that patients taking orlistat had a 2.7-kg weight loss niques, and psychotherapy (TABLE 2 ) . A substantial body of literature is available for assessment of these options.
Morbidly obese patients typically are more than 100 lb (~45 kg) overweight. Therefore, they need to be managed with treatments that have the potential to achieve substantial weight reductions and thereby correct obesity-related metabolic abnormalities. To date, all nonsurgical treatments for obesity have demonstrated maximum average weight-losses of 3 to 6 kg. 6, 47 In addition, noncompliance rates approximate 50%, and relapse rates after cessation of treatment approach nearly 100%. 6, 47 Clearly, the primary care physician has few effective nonsurgical options for the morbidly obese patient.
Lifestyle changes
Modification of diet (restriction of caloric intake) and aerobic exercise (increased energy consumption) form the mainstay of lifestyle changes. Dietary changes can decrease weight approximately 3 to 6 kg and adding exercise to a diet may be more effective than diet alone. 6 No specific type of diet (eg, low-calorie vs low-carbohydrate) has been shown to be superior when caloric intakes of the diets are equivalent. 6, 48 When used as monotherapy, exercise offers minimal improvement, but it may prevent additional weight gain and improves cardiovascular fitness. 6 As mentioned, the major concerns about using lifestyle changes in the treatment for the morbidly obese patient are the relatively small impact on the patient's total weight, the high rates of attrition, and the high rates of weight regain over time. 47 
Pharmacologic therapy
Numerous medications have been used in the management of morbid obesity, but only two of them,
BMI and cancer mortality
Risk for death from all cancers increased as BMI increased in more than 900,000 US adults followed for 16 years. Morbidly obese persons (BMI ≥40 kg/m 2 ) had the highest cancer death rates, with overall rates 52% higher in men and 62% higher in women, compared with normal-weight adults. The most common weight-related cancer was liver cancer in men (combined risk ratio, greater than patients taking placebo (95% CI, 2.3-3.1). 49 Attrition rates ranged from 14% to 52% (average, 33%). Orlistat is associated with a high incidence of gastrointestinal side effects; they occurred 16% to 40% more often in orlistat patients than in placebo patients. The most common of these, occurring in 15% to 30% of patients taking orlistat, were fatty/oily stool, fecal urgency, and oily spotting. Fecal incontinence occurred in 6% of patients in the 3 studies that reported this side effect.
Most orlistat trials also excluded patients with BMIs greater than 40 kg/m 2 , which limits application of these data to patients with class III obesity. 49 Both orlistat and sibutramine may improve quality-of-life parameters and may have a modest beneficial impact on lipid levels and metabolic parameters (eg, blood glucose, hemoglobin A 1c ). However, discontinuation of therapy is associated with return of previously lost weight. 49 
Alternative therapies
Obese patients often turn to alternative therapies such as hypnosis, acupuncture, and over-the-counter dietary supplements. Studies of hypnosis and acupuncture have shown that these techniques do not provide consistent improvement over placebo (ie, sham procedure). 50, 51 Over-the-counter dietary supplements that have been studied include chitosan, chromium picolate, Ephedra sinica, Garcinia cambogia, glucomannan, guar gum, hydroxy-methyl butyrate, plantago psyllium, pyruvate, yerba maté, and yohimbe. A systematic review of such studies concluded that none of these agents have shown consistent results in promoting weight loss; moreover, safety is a significant concern with several of them. 52 Thus, they cannot be recommended for use in clinical practice, at least until further research has been performed.
Psychotherapy
Structured psychotherapy aimed at weight reduction includes behavioral modification techniques (eg, stimulus control, self-monitoring, and cognitive restructuring) that increase compliance with dietary changes, exercise regimens, or both. 53 No one technique has been proven superior when judged by the amount of weight lost. 6 The majority of weight loss in patients undergoing psychotherapy and supervised lifestyle change occurred during the first year of treatment. At 5-year follow-up, there was no statistically significant difference between intervention and control groups. 6 Programs with the most patient contact tended to produce the largest weight loss. 
Summary
The family physician is often the morbidly obese patient's first contact with the health care system, there by providing an opportunity to influence management in a patientoriented manner that focuses on outcomes such as weight loss, associated comorbidities, and quality of life. Nonsurgical treatments for morbid obesity have significant limitations including minimal total weight loss, little or no effect on comorbidities and quality of life, and lack of sustainment over time. Bariatric surgery, on the other hand, offers greater and longer-lasting weight loss 54 and better improvement in clinically relevant outcomes. 21, 22 Sackett wrote that evidence-based medicine is "the integration of the best research evidence with clinical expertise and patient values." 55 Because we now have access to a significant body of literature on the management of obesity, we can initiate evidence-based discussions with patients, which may help to create a treatment plan aimed at reducing the morbidity associated with severe obesity. For the patient with morbid obesity, this will likely include a discussion about bariatric surgery. s T he weight loss that occurs after bariatric surgery is achieved and maintained through restriction of food intake, malabsorption of food, or both. Ideally, eating behavior will be modified after surgery-patients are likely to consume smaller quantities of food more slowly.
The number of bariatric procedures performed around the world has grown markedly and probably will increase exponentially as surgery is recognized as an effective treatment. Its risks are decreasing, and its benefits include the reduction, if not elimination, of many comorbidities. A 31-country survey performed by the International Federation for the Surgery of Obesity (IFSO) showed that the worldwide frequency of bariatric surgery has increased from 40,000 in 1998 to more than 146,000 in 2003. 
Weight loss after surgery
For practical and ethical reasons, it is currently impossible to perform a true randomized controlled trial (RCT) of bariatric surgery; that is, a blinded study in which patients are randomized to surgery or placebo. Most studies have been RCTs that compared different surgical procedures or surgery to nonsurgical management (drugs and/or diet or no treatment), nonrandomized controlled studies of surgery vs nonsurgery, and prospective cohort studies of surgery vs nonsurgery. In recent years, several systematic reviews of these data have been completed, permitting an assessment of the effects of bariatric surgery on weight loss, comorbidities, and quality of life.
Analysis of pooled data from randomized controlled trials of bariatric surgery in the United States, United Kingdom, and Canada found dramatic weight reduction across the board. 2 In 5 US trials reviewed by the National Institutes of Health, mean weight loss was 76 kg (range, 9.7-159) after 1 to 4 years. 2 Mean weight loss in a UK National Health Service review of 6 trials was 45.1 kg (range, 9.7-57.9) after 1 to 4 years, while mean weight loss in 4 randomized trials and 1 prospective cohort study reviewed by the Canadian Task Force on Preventive Health Care was 29.9 kg (range, 17-45.5) after 2 to 5 years. 2 Wound infection, gastric leaks, and other complications were reported, and up to 25% of patients required revisional procedures within 5 years. However, operative mortality was extremely low (<1%).
A more recent Cochrane review of 18 trials involving 1,891 subjects concluded that, on average, morbidly obese patients who underwent bariatric surgery lost 23 to 28 kg more weight at 2 years than patients who were managed nonsurgically. 3 The Swedish Obese Subjects (SOS) study, initiated in 1987, is an ongoing prospective cohort study involving approximately 2,000 matched pairs treated with either bariatric surgery (vertical banded gastroplasty, gastric banding, or gastric bypass) or conventional weight-loss measures (ie, the best nonsurgical options available). At the 2-year mark, patients in the surgery cohort had lost an average of 28 kg (CI, 26.9-29.1), compared with 0.5 kg (CI, -0.2 to 1.2) for patients who underwent conventional obesity treatment (FIGURE 1). After 
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sis of the long biliopancreatic limb to the Roux limb to create a short (50 cm) common channel. Potential complications include malodorous diarrhea, flatulence, anemia, stomal ulcers, bone demineralization, and protein malabsorption.
The duodenal switch was pioneered by Marceau and colleagues (1993) and Hess and Hess (1998). 6 This is a complicated procedure in which a greater curvature sleeve gastrectomy is performed to leave a stomach with a capacity of approximately 100 mL, the duodenum is divided, and the enteric limb is anastomosed to the postpyloric duodenum. Like biliopancreatic diversion, the duodenal switch may be associated with diarrhea, flatulence, iron malabsorption, and calcium and protein malabsorption. These can be reduced or avoided by the use of mild antidiarrheal agents and mineral supplements, and maintenance of a diet containing 65 to 80 gm of protein per day.
Malabsorptive/restrictive procedures
The first gastric bypass procedure was developed by Mason and Ito in the mid-1960s, with subsequent variations by Alden, Griffen, and associates; Linner and Drew; Torres and Oca; and others. 6 All combine intestinal malabsorption with gastric restriction, but rely loss of 20 kg (CI, [18] [19] [20] [21] [22] in surgical patients and of 0.7 kg (CI, -0.8 to 2.2) in controls. 4 
Operative procedures
Since bariatric surgery is the only broadly successful treatment for morbid obesity, physicians should familiarize themselves with commonly used operative procedures and their impact on the comorbidities associated with extreme obesity. There are 4 main categories of procedures: malabsorptive (eg, biliopancreatic diversion, duodenal switch), malabsorptive/restrictive (eg, Roux-en-Y gastric bypass), restrictive (eg, vertical banded gastroplasty, gastric banding), and neither malabsorptive nor restrictive (eg, gastric or vagal pacing). Despite their relative complexity, all can be performed laparoscopically, as well as by open abdominal surgery. Recently, robotics have been introduced into laparoscopic bariatric surgery.
Malabsorptive procedures
The current generation of malabsorptive procedures is descended from the jejunoileal bypass, the first operation to be performed for the purpose of weight reduction. 5, 6 Introduced in 1953-1954 by Varco and the team of Kremen, Linner, and Nelson, the jejunoileal bypass was highly effective for weight loss, but had unacceptably high morbidity. 5, 6 Gas-bloat syndrome, steatorrhea, electrolyte imbalance, hepatic fibrosis and failure, nephrolithiasis, and impaired mentation were among the complications that led to gradual abandonment of the jejunoileal bypass in favor of the gastric bypass in the 1970s and 1980s.
Newer malabsorptive procedures such as the biliopancreatic diversion and the duodenal switch share a key feature that averts most of these complications (FIGURE 2). No segment of the intestine is allowed to remain stagnant and become a breeding ground for bacteria. The surgeon creates an enteric limb for transit of food and a biliopancreatic limb for transit of bile and pancreatic juice. These join in a common channel where digestion and nutrient absorption take place. The biliopancreatic diversion is also known as the Scopinaro procedure after Nicola Scopinaro, its creator and staunchest advocate. 6 Since introducing the procedure in 1979, Scopinaro has made a number of modifications. The current operation consists of a horizontal partial gastrectomy with closure of the duodenal stump, gastrojejunostomy with a long Roux limb, and anastomo- Brolin) to further enhance malabsorption. 6 It may cause severe vitamin, mineral, and nutrient malnutrition and should be reserved for patients who are super-obese or have failed primary Roux-en-Y bypass.
While considerably safer than the jejunoileal bypass, the Roux-en-Y gastric bypass is not without problems. Postoperative complications include the "dumping" syndrome, iron deficiency anemia, and lifelong vitamin B 12 malabsorption. Should the bypassed distal stomach become obstructed, the resulting dilation can lead to gastric rupture-a life-threatening complication. The procedure also deprives care providers of the ability to visualize the distal stomach and duodenum.
Restrictive procedures
In the 1970s and 1980s, bariatric surgery was simplified by introduction of a number of purely restrictive gastric operations: gastroplasty, gastric partitioning, banded or ringed vertical gastroplasty (partial gastric partitioning at the proximal gastric segment), and gastric banding (placement of an adjustable or nonadjustable band around the stomach to create a small pouch) (FIGURE 4). These are the least invasive of bariatric procedures because the stomach is not cut or stapled, no anastomoses are required, and the natural physiologic passage of food is not altered.
Patients who eat more than can be tolerated at one primarily on the latter for weight loss. The Roux-en-Y bypass involves construction of a small upper gastric pouch (currently 20 mL or less) that empties food into the small intestine through a Roux limb gastrojejunostomy (FIGURE 3). The degree of malabsorption is determined by the extent of the bypass, which at a minimum includes the distal stomach, the duodenum, and the first segment of the jejunum. A modification known as the long-limb or distal Roux-en-Y bypass, involving a long Roux limb and a long bypassed limb that join to create a short common channel, was designed by Torres and Oca (and later 
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Restrictive procedures F I G U R E 4 Vertical banded gastroplasty
Gastric banding sitting may experience vomiting, especially during the early postoperative period. Other complications include the lodging of food particles or pills within the band or ring, and occasional band slippage or erosion. While morbidity is low, weight loss also may tend to be less dramatic than with other forms of bariatric surgery.
New procedures
In the 1990s, procedures that do not rely on either malabsorption or restriction were introduced into bariatric surgery. Gastric and vagal pacing have been tested in animals and in preliminary human trials. 6 A hypothesis behind this approach is that induced gastric paresis and/or afferent vagal central nervous system stimulation will produce satiety and, as a consequence, weight loss. The electrical stimulation procedures are simple and easy to perform, but it is too early to determine their place in the armamentarium of bariatric surgery.
Frequency of surgery by type
Gastric bypass operations account for 65% of bariatric procedures performed worldwide, according to the IFSO survey. 1 The most common procedure in the world is laparoscopic Roux-en-Y gastric bypass (26% of all operations), followed by laparoscopic gastric banding (24%), open gastric bypass (23%), laparoscopic long-limb gastric bypass (9%), open long-limb gastric bypass (7%), vertical banded gastroplasty (5%), and biliopancreatic diversion/duodenal switch (5%).
About 57% of bariatric procedures in the United States are performed laparoscopically, compared with 63% worldwide. Similarly, gastric banding is performed less frequently than gastric bypass in the United States; 
Is there a clear winner?
The heterogeneity of the bariatric surgery data makes it difficult to draw conclusions about the superiority of one procedure over another. Studies differ with regard to procedural variations, measures of weight change, and length of follow-up. Degree of weight loss must be balanced against operative risk, short-and long-term morbidity, and the need for later revisional surgery. Moreover, while later morbidity is heavily procedure-dependent, operative risk depends largely on the skill of the surgeon and may vary for patients undergoing the same operation.
In the Cochrane review previously cited, 3 gastric bypass was associated with significantly greater weight loss and fewer revisions or conversions than gastroplasty, but also with more side effects and postoperative deaths. Greater weight loss, and fewer side effects and reoperations, occurred with adjustable gastric banding than with vertical banded gastroplasty. Weight loss was similar with open and laparoscopic procedures; however, the laparoscopic approach had fewer serious complications. Laparoscopic surgery was associated with reduced blood loss, fewer intensive care unit stays, reduced length of hospital stay, reduced days to return to activities of daily living, and reduced days of return to work. Because all studies included in the Cochrane analysis had the potential for significant bias, the investigators cautioned that these results should be viewed as tentative-the relative safety and efficacy of different bariatric procedures remain to be determined.
Impact on comorbidities
The effects of bariatric surgery on obesity comorbidities are rapid and profound (TABLE 1). In a landmark 1995 article, Pories et al reported achievement of long-term control of obesity and type 2 diabetes in approximately 600 morbidly obese patients treated with gastric bypass surgery. 7 Weights fell from a preoperative mean of 304 lb (138 kg) to 192 lb (87 kg) by 1 year and were maintained at under 207 lb (94 kg) for 14 years. In patients with adequate follow-up, 83% of those with type 2 diabetes and 98.7% of those with glucose impairment maintained normal levels of plasma glucose, glycosylated hemoglobin, and insulin for an average of 7.6 years.
Normalization of glucose metabolism often occurred within days-even before significant weight loss had occurred-and was durable despite the fact that patients remained above ideal body weight follow- ing surgery. Gastric bypass also corrected or alleviated other comorbidities of morbid obesity, including hypertension, obstructive sleep apnea, cardiopulmonary failure, arthritis, and infertility. 7 In the SOS study, incidence of diabetes was reduced 32-fold in surgical patients relative to controls at 2 years. At 8 years, there was still a 5-fold reduction in diabetes incidence. 4 Incidence of hypertension was reduced 2.6-fold in surgical patients relative to controls at 2 years. However, by 8 years the surgical patients' blood pressure had reverted to control values despite maintenance of a 16% weight reduction. 4, 8, 9 Buchwald and colleagues recently conducted a systematic review of published observational and interventional trials involving bariatric surgery. 10 A total of 134 studies (5 randomized controlled trials, 28 nonrandomized controlled trials or series with comparison groups, and 101 uncontrolled case series) that included 22,094 patients were analyzed to determine the impact of specific bariatric surgical procedures on weight loss, operative mortality outcome, and 4 obesity comorbidities (diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea). Results are summarized in Table 1 .
For purposes of analysis, surgical procedures were grouped into 5 main categories: (1) gastric banding, (2) gastric bypass (this category consisted principally of Roux-en-Y variations but included all procedures with a gastric bypass component, such as gastroplasty with gastric bypass and banding with gastric bypass), (3) gastroplasty, (4) biliopancreatic diversion or duodenal switch, and (5) 7 ) of patients treated with gastric banding. Thus, the predominantly malabsorptive and mixed malabsorptive/restrictive procedures were more effective in resolving diabetes than the purely restrictive procedures, especially gastric banding. An important unanswered question is whether malabsorptive procedures have a greater impact than restrictive procedures on the hormonal milieu of the gut-specifically, on gastrointestinal satiety mediators such as leptin, ghrelin, resistin, acylation-stimulating protein, adiponectin, entroglucagon, and cholecystokinin. This hypothesis is currently being investigated.
Hyperlipidemia also improved in at least 70% of patients. Improvement was seen in all outcome categories (hyperlipidemia, hypercholesterolemia, hypertriglyceridemia) and across all surgical procedures. Maximum improvement occurred in patients treated with biliopancreatic diversion or duodenal switch (99.1% [95% CI, 97.6-100]) and those treated with gastric bypass (96.9% [95% CI, 93.6-100]).
Hypertension was resolved in 61.7% of patients and resolved or improved in 78.5%. This was not sur-prising, since even a modest (eg, 10%) weight loss can significantly lower blood pressure. Unlike the case with type 2 diabetes and hyperlipidemia, the reduction in hypertension appeared to be independent of the type of surgery performed.
Obstructive sleep apnea was resolved in 85.7% of patients and was resolved or improved in 83.6% of patients. The extracted studies showed improvements in oxygen saturation, decreases in arterial carbon dioxide, and increases in arterial oxygen content. All of these changes resulted primarily from the increase in diaphragmatic excursion brought about by reduction in obesity-induced intra-abdominal pressure.
Increased life expectancy
Given the scope of the reductions in diabetes, hyperlipidemia, hypertension, obstructive sleep apnea, and other obesity comorbidities that accompany bariatric surgery, it should come as no surprise that patient life expectancy is also increased. Christou et al recently conducted a large observational study to test the hypothesis that surgically induced weight loss reduces long-term morbidity, mortality, and healthcare use in patients with morbid obesity.
11
None of the 1,035 surgery patients or 5,746 age-and gender-matched severely obese controls had medical conditions other than morbid obesity at study entry. Mean follow-up was 5 years (range, 1-16). Bariatric surgery (Rouxen-Y gastric bypass) resulted in a mean percentage excess weight loss of 67.1% (P<0.001), as well as significant reduction in risk for the development of cardiovascular disease (including hypertension), cancer, endocrine disorders (including type 2 diabetes), infectious disease, respiratory conditions, and psychiatric disorders. Risk of digestive disorders increased in the surgery cohort, and there was no difference in the risk of hematologic disorders in the 2 groups. Mortality in the bariatric surgery cohort was 0.68% over 5 years compared with 6.17% in controls (RR 0.11, 95% CI, 73-96), which translated to an 89% reduction in relative risk of death (P<0.001) (FIGURE 5).
Quality of life: Before and after
Studies of health-related quality of life in patients undergoing bariatric surgery have shown consistent improvement in comfort, mobility, physical activity, social involvement, sexual functioning, self-confidence, and self-esteem following surgery, and loss of feelings of helplessness and failure. 12 Cross-sectional data from the SOS study revealed that prior to surgery, health-related quality of life (HRQOL) was far below that of an age-matched reference population. The HRQOL of the SOS subjects was worse than that of patients with rheumatoid arthritis or spinal cord injuries, and comparable to that of patients with generalized malignant melanoma. Two years postoperatively, HRQOL had improved in a dose-dependent fashion relative to weight loss, regardless of which measuring instruments were used. 4 In another cross-sectional study, van Gemert and colleagues used the Nottingham Health Profile (NHP)-I and II and a visual analogue scale to compare 62 patients who had undergone either vertical banded gastroplasty or Roux-en-Y gastric bypass with a control group of 20 preoperative morbidly obese patients. 13 Mean follow-up time was 7-plus years. Significant differences were found on the NHP-II (P<0.0001), the visual analogue scale (P<0.001), and in the domains of mobility (P<0.0001), energy (P<0.001), and emotional reaction (P<0.001) on the NHP-I in favor of the postoperative patients (FIGURE 6). Better quality-of-life outcome was correlated with greater weight loss and shorter postoperative follow-up. No correlation was found between quality-of-life outcome and either the type of surgical procedure used or the surgical complication rate.
A noteworthy finding was that unemployment was reduced from 80% to 53% in the postoperative group as a whole and from 84% to 64% in postoperative women. Other studies in the United States and Sweden 
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have shown similar increases in employment and/or income after bariatric surgery. It should be noted that US law prohibits employment discrimination based on physical attributes that do not affect job performance.
In both of the studies cited above, postoperative quality of life tended to decrease somewhat over the long term. Since HRQOL correlates with the degree of weight loss, this may simply reflect the well-known tendency of bariatric surgery patients to regain a modest portion of their lost weight after 2 years. In addition, it has been suggested that patients derive considerable psychological support from their postoperative visits and may experience an emotional downturn when those visits cease.
At no time, however, did quality of life drop to the level of obese controls. Van Gemert and colleagues emphasized that this remained true even in patients who experienced significant surgical complications such as stoma stenosis or band erosion or disruption. Noting that other studies have also found surgical complications to be a nonissue, they commented: "The fact that patients with complications nevertheless experienced a significant improvement in quality of life compared with the control group highlights the severity of the mental and physical suffering ... before surgery. Apparently, these patients prefer a nonobese state with surgical complications over an obese state." 13 
Matching patient and procedure
A morbidly obese patient may be broadly matched to the most suitable bariatric procedure on the basis of several variables: 14 1) BMI. Some bariatric procedures induce more weight loss than others. Patients with the highest BMIs may be guided to procedures that achieve the most weight loss (eg, biliopancreatic diversion with duodenal switch, long-limb Roux-en-Y gastric bypass).
2) Age. Older patients (>40 years) may be candidates for the more definitive procedures (eg, biliopancreatic diversion, duodenal switch, and long-limb Rouxen-Y gastric bypass). Despite their complexity, increased operative risk, and long-term surgically induced morbidity, such procedures have a lower risk for failure and need for reoperation.
3) Gender, race, and body habitus. Women may lose less weight after a given procedure than men. Similarly, African Americans and possibly Hispanics tend to lose less weight after a given procedure than Caucasians. Central (as opposed to peripheral) obesity in men and android (as opposed to gynecoid) obesity in women appear to be associated with more comorbidities that increase operative risk.
Patients in whom combined gender, race, and body habitus is 'unfavorable' are candidates for a more definitive operation. If combined status is 'favorable,' a simpler operation (eg, gastric banding) may be appropriate. 4) Comorbidities. The patient with few serious preoperative comorbidities clearly has a better long-term prognosis than the patient with numerous serious comorbidities. They can be guided to a simpler, faster operation, despite the increased risk for subsequent revisional surgery. When comorbidities predict a poor longterm prognosis, a more definitive operation with a lower risk for reoperation is recommended.
Conclusion
Morbidly obese patients who elect to undergo bariatric surgery experience significant reductions not only of weight but also of obesity comorbidities, including diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea, with resultant improved life expectancy. The quality of life of these patients also has been shown to improve. While bariatric surgical procedures differ with regard to degree of weight loss, short-and longterm morbidity, and need for revisional surgery, the data are difficult to interpret. Thus far, no single bariatric procedure has emerged as clearly superior to others. s 
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Amelioration of comorbidities should be the primary goal when contemplating surgery. Indeed, in the severely obese patient, surgery is the only treatment that has been shown to cure or ameliorate many of these chronic medical conditions. In addition to the above criteria, potential candidates must be well-informed about bariatric surgery, motivated, and have realistic expectations. Operative risks must be acceptable, and patients should understand the ways in which their lives will change after the operation. They also should be prepared to accept longterm postsurgical follow-up.
Contraindications to bariatric surgery include untreated major depression or psychosis, certain personality disorders (eg, bipolar, schizoaffective), active alcohol or drug abuse, and noncompliance with preoperative medical, nutritional, and psychologic management. Weight-loss surgery is no longer denied to patients older than 65 years; however, surgical risks may outweigh benefits in patients over 70 years of age.
Bariatric surgery in children and adolescents remains controversial. Inge et al noted that surgery in severely obese teenagers (12-18 years) with significant associated medical conditions (metabolic syndrome, diabetes, obstructive sleep apnea, reactive airway disease, steatohepatitis) is safe and has resulted in resolution of comorbidities. 4 Bariatric surgery programs and insurance carriers invariably insist that patients meet some or all of the above conditions. However, criteria vary from region to region and state to state, and it is therefore recommended that the family physician obtain specific inclusion and exclusion criteria from the patient's insurance carrier before making a referral for bariatric surgery.
Preoperative evaluation and care
A comprehensive team approach to patient management is advocated by most bariatric surgeons and insurance carriers. An ideal team includes, at a minimum, representatives from 4 specialties: medicine, nutrition, psychology/psychiatry, and surgery. 5 The team evaluates the patient, treats conditions that require stabilization before surgery, and participates in postoperative education and management. In addition to providing optimal care in each area of expertise, team members should be able to communicate constructive insights to help the patient fully appreciate the lifelong lifestyle changes necessitated by bariatric surgery.
Medical evaluation.
To decrease perioperative morbidity, the medical professional whether a family physician, internist, endocrinologist, gastroenterologist, or cardiologist should ensure optimal preoperative control of such common comorbid conditions as hypertension, hyperglycemia, dyslipidemia, liver abnormalities, and sleep disorders. A modest preoperative weight loss of 5% to 10%, which is mandatory in many bariatric surgery programs, is an effective intervention that can facilitate significant improvement in many comorbidities.
A thorough physical examination and disease-specific testing are also recommended. Cardiovascular assessment, via a stress imaging study such as echocardiography or nuclear imaging, should be considered in patients older than 50 years and in those whose obesity-related comorbidities (especially diabetes, hypercholesterolemia, and hypertension) have been present for more than 10 years. Administration of dobutamine or adenosine often is needed to achieve target heart rates in patients with limited mobility.
A 12-lead EKG should be performed to assess, among other things, for Q-Tc interval prolongation. Obese patients with acquired Q-Tc interval prolongation have increased risk for postoperative malignant arrhythmias. 6 Sleep apnea is common in the severely obese, but is often overlooked or misdiagnosed as depression or chronic fatigue syndrome. A polysomnogram or, if it is not available, nocturnal pulse oximetry should be arranged for patients with loud snoring and documented apneic episodes, significant daytime somnolence, and/or early morning headache.
A routine workup that includes complete blood count, liver function studies, and disease-specific serologies may be augmented by additional testing, such as right upper quadrant ultrasound to assess for cholelithiasis and liver size and steatosis, stool analysis for Helicobacter pylori antigen, and measurement of bone mineral density.
Preoperative placement of an inferior vena cava filter may be considered in patients with a high risk for deep vein thrombosis and pulmonary embolism. 7 However, prophylactic use of such filters needs to be validated by prospective, randomized trials. White et al, for example, found that a vena cava filter did not reduce the incidence of pulmonary embolism and, in patients with previous pulmonary embolism, it was associated with a higher incidence of rehospitalization for venous thrombosis.
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Nutritional evaluation. A registered dietitian or nutritionist is instrumental in preoperative weight-loss counseling and, to that end, will assess food intake and identify eating triggers such as emotional upset.
Counseling also includes repeated review of the progressive dietary stages that the patient will be expected to follow after surgery. Postoperatively, the dietitian/nutritionist will monitor the patient for adequate nutrient intake.
Psychologic/psychiatric evaluation. Assessment of mental status should be done by a psychologist or psychiatrist who is familiar with the psychologic/emotional abnormalities common to the morbidly obese, as well as the ramifications of bariatric surgery. The focus of the mental health examination is on eating disorders/behaviors (binge eating, in particular), uncontrolled major depression, and personality disorders. The mental health professional also needs to confirm that the patient has realistic expectations of surgery and fully understands and accepts the postoperative lifestyle and behavioral changes that will be required. The strength of the patient's support network is another important issue, given the high rates of marital and undergoing malabsorptive procedures (eg, gastric bypass) and those assigned to restrictive procedures (eg, vertical banded gastroplasty, adjustable lap band) to accommodate differences in rate of weight loss and behavioral changes.
Perioperative care
Bariatric surgery today is a relatively safe endeavor with short hospital stays, the result by and large of specific improvements in surgical technique and general improvements in the surgical milieu, such as anesthesia and ventilation. 9 A standard, comprehensive protocol that is designed to ensure early ambulation, aggressive pulmonary toilet, adequate pain control, and diligent blood glucose control will decrease perioperative morbidity and shorten length of stay. Depending on which surgical procedure was performed, patients are usually discharged 1 to 7 days after surgery. Therefore, immediate and frequent postoperative follow-up by the bariatric team is essential to ensure adequate hydration and prompt detection of early postoperative complications (TABLE 2).
Postoperative care
As with preoperative care, postoperative care of the bariatric surgery patient is comprehensive in nature and best achieved with the team approach. Postoperative involvement of the medical, nutritional, mental health, and surgical team members maximizes the likelihood of achieving optimal weight loss and resolution of comorbidities.
Early postoperative period
Anastomotic leak. During the early postoperative period (1-4 weeks) , leakage from the gastrojejunal, gastroduodenal, or jejunojejunal anastomosis may develop in patients undergoing malabsorptive procedures, such as Roux-en-Y gastric bypass or biliopancreatic diversion with duodenal switch. Because it is potentially life-threatfamily discord that occur after bariatric surgery.
Surgical evaluation. After the medical, nutritional, and mental health evaluations have been completed and adequate metabolic control has been achieved, the patient is referred to the bariatric surgeon who also assesses the patient's motivation and expectations. In addition, the surgeon discusses the risks and benefits of the various surgical approaches after which the most appropriate technique is selected.
Support groups. Preoperative attendance of support-group meetings is mandatory in most bariatric programs. Here patients are exposed to other preoperative candidates as well as to patients who have undergone weight-loss surgery. Direct contact with postoperative patients is particularly beneficial, as it provides firsthand accounts of successful and less than successful adaptation to the behavioral and lifestyle changes. In larger bariatric programs, separate support groups often are created for patients 
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ening, this complication has been well publicized Reported frequencies in large series (≥2,000 patients) have ranged from <1% to >3%. 10, 11 Anastomotic leaks most commonly occur during a surgeon's first 75 laparoscopic bypass procedures. 12, 13 The leak usually manifests while the patient is hospitalized; however, signs and symptoms may not appear until 7 to 14 days after surgery. The primary care physician should, therefore, be familiar with their signs and symptoms.
The most sensitive signs of anastomotic leak are sustained tachycardia of >120 bpm.
14 Additional signs and symptoms include fever, shoulder pain (usually in the left), abdominal pain, shortness of breath, and respiratory rate of >22 bpm, increased thirst, and hypotension.
When an anastomotic leak is suspected, the recommended workup includes a barium swallow or CT scan with contrast, complete blood count with differential, comprehensive metabolic panel, and chest X-rays (posterior-anterior and lateral).
If diagnosed early, the leak can be managed conservatively without long-term sequelae in most cases. Early management typically involves total parenteral nutrition (NPO) and antibiotic therapy. Percutaneous drainage of any collection may be warranted to prevent abscess formation. In the unstable patient, surgical reexploration with repair, drainage, and G-tube placement may be indicated.
Pulmonary embolism. In contrast to the anastomotic leak, pulmonary embolism is not widely publicized as a cause of death after bariatric surgery; nevertheless, it may be the most frequent cause of operative mortality (1-30 days). All patients are at risk for deep venous thrombosis/pulmonary embolism (DVT/PE) regardless of the procedure performed. Hence, aggressive prophylaxis is warranted. 15 Definitive data on the incidence of pulmonary embolism after bariatric surgery are lacking; estimates place it at 2% to 4%. In a retrospective study of DVT/PE prophylaxis by Miller and Rovito, the 30-day incidence of pulmonary embolism was 1.2%. 15 An effective prophylactic treatment regimen for DVT/PE consists of low-molecular-weight heparin administered intraoperatively and twice a day until discharge, lower extremity compression devices, and early ambulation. As mentioned, preoperative placement of an inferior vena cava filter is an option in high-risk patients, such as those with a history of DVT/PE, clotting disorders, or significant venous stasis. 7 As with anastomotic leak, DVT/PE can occur as late as 2 weeks after surgery, so familiarity with the signs and symptoms is important. Nausea and vomiting. Intermittent nausea and vomiting often occur soon after bariatric surgery. The complication is by no means life-threatening but can be frustrating for the patient and primary care physician. Causes of nausea include dehydration, pain medication, administration of vitamins, pouch size, and eating too quickly, eating too much, or not chewing adequately. Patients who are unable to keep down fluids and solids for a 24-hour period should be evaluated for possible obstruction and/or dehydration.
Nausea typically responds to rehydration and antiemetic medication administered orally, per rectum, or intravenously. Repeated administration of intravenous fluid may be necessary.
Patients who are also vomiting need to be given thiamine/folate and a multiple vitamin in the intravenous infusion to prevent thiamine deficiency and Wernicke's encephalopathy. The latter may occur after any gastric surgery. Often, administration of thiamine alone immediately alleviates nausea and vomiting.
Repeated vomiting may cause pouch swelling and anastomotic narrowing, which, in turn, may exacerbate nausea and vomiting. In addition, pouch size and the angle of the anastomosis into the jejunum can contribute to emesis. In rare instances, total parenteral nutrition may be necessary until the patient can tolerate adequate oral feeding.
Wound complications.
Wound infection or cellulitis occurs in 5% to 20% of patients who undergo an open procedure. Management often requires no more than opening the incision and local packing. An extended course of antibiotic therapy may not be necessary.
Other early complications. Diarrhea is frequent after bariatric surgery and may be caused by new onset (often temporary) lactose intolerance, which can be resolved with ezymatic therapy or withdrawal of dairy products. Other causes of diarrhea include occult ingestion of sugar contained in prescription and over-thecounter drugs, malabsorption or dumping syndrome, and Clostridium difficile colitis.
More common than diarrhea, however, is constipation, which results from the high protein intake, decreased fruit and vegetable intake, and administration of narcotic pain medication after surgery. the early postoperative period. Insulin requirements fall significantly immediately after weight-loss surgery, and other medications need to be reduced in dosage or withdrawn. In patients who were receiving preoperative antidiabetic therapy, oral glycemic agents should be replaced with sliding-scale, short-acting insulin. Similarly, antihypertensive medications should be reduced in dosage or discontinued and diuretics should be withheld. Antilipid agents also should be held during the early postoperative period, given their tendency to produce nausea in some patients.
Essential medications should be administered in regular-release rather than sustained-release formulations to offset the altered gastrointestinal absorption that occurs after malabsorptive procedures. Moreover, patient tolerance of medications can be improved by crushing the tablets or giving a liquid formulation of the drug during the first 4 postoperative weeks. By the fifth week, bisecting the tablets is usually sufficient.
Late postoperative period
The most common late complications seen after Rouxen-Y gastric bypass are gallstones, stomal stenosis, and marginal ulcers. 16 Gallstones often develop after rapid weight loss, be it surgically or nonsurgically induced, For this reason, some surgeons opt for prophylactic cholecystectomy at the time of surgery. When cholelithiasis is documented on preoperative ultrasound or palpated intraoperatively, simultaneous cholecystectomy probably is warranted.
Marginal ulcers and stomal stenosis occur in 10% of gastric bypass patients. Chronic use of aspirin, nonsteroidal anti-inflammatory agents, and some other medications has been associated with significantly increased risk for these complications. Therefore, the agents listed in TABLE 3 should be avoided after malabsorptive procedures. Marginal ulcers respond to treatment with proton pump inhibitors and stenosis of the gastrojejunostomy is readily dilated by an experienced endoscopist.
Nutritional management
Immediately after surgery, patients are placed on a sugar-free, clear-liquid diet, from which they progress slowly, as tolerated, to a prudent low-fat diet. • Eat slowly; no more than 1 oz every 10 minutes.
• If you feel full, stop eating; otherwise, vomiting can occur.
• Continuous overeating will stretch your new pouch.
• Do not consume foods and beverages at the same time. Wait 30 minutes before eating and another 60 minutes after eating before drinking fluids.
• Avoid cold or hot liquids and foods that are high in sugar or fat; they cause dumping syndrome.
• Continue food diary to track protein and fluid intake.
STAGE 4: Low-fat, low-sugar foods
Begin: Approximately 8 weeks after surgery Duration: Lifelong Diet: Use the Food Pyramid as a guide. Every day, try to eat 6 oz of meat or high-protein foods, 2 cups of milk products, 2-3 servings of grains or starch, 2 servings of vegetables, and 2-3 servings of fruit.
Fluid Goal: 48-64 oz/day Protein Goal: 60 gm/day minimum
• Gradually introduce new foods to your diet 1 at a time. Go slowly with fresh fruits and vegetables.
• If a food is not tolerated, wait 2-4 weeks before reintroducing it.
• Consume protein at each meal.
• Take at least 30-60 minutes to consume a typical meal, which should fit on a dish no larger than a salad plate.
• Continue to keep a food diary to ensure adequate protein and fluid intake.
lished a series of specific diets with recommended stages of progression ( Dumping syndrome may occur in patients who undergo a combined restrictive/ malabsorptive procedure such as the Roux-en-Y gastric bypass. Dumping is the jejunum's response to the rapid introduction of a large amount of undigested carbohydrate. Enteroglucagon and other gastrointestinal hormones cause an influx of fluid into the lumen of the small intestine, which is usually followed by runny nose, excessive salivation, nausea, tachycardia, syncope or presyncope, vomiting, and diarrhea. 17 The small bowel gradually adapts to the anatomic changes of surgery, and dumping syndrome usually resolves in 6 to 12 months. Although uncomfortable, the syndrome provides valuable negative reinforcement for patients to avoid concentrated sweets and carbohydrates.
Psychologic follow-up
After surgery, patients need early and frequent contact with a psychologist or psychiatrist to address such issues as adjustment to behavioral and dietary changes, depression, marital/family discord, poor selfimage/esteem, and impaired coping mechanisms). Continued participation in support groups is beneficial and recommended. Many online support groups and chat rooms have appeared recently. Visiting such sites (eg, Association for Morbid Obesity Support at www.obesityhelp.com/morbid obesity/index.html) may help to reinforce goals of the bariatric program.
Medical management
Patients who have undergone a malabsorptive procedure require lifelong supplementation with vitamins and (TABLE 5) . 18 Gastric bypass patients should receive 40 to 65 mg/day of iron, which can be obtained from most prescription prenatal vitamin supplements. Additional iron may be warranted, especially in menstruating women. Folate deficiency is rare after malabsorptive procedures. The recommended 800 to 1,000 mcg/day of folate is generally contained in over-the-counter multiple vitamins.
Vitamin B 12 deficiency occurs in about one-third of patients after malabsorptive surgery. An average dose of 350 mcg/day of sublingual B 12 is recommended. Intramuscular injections of 1,000 mcg of B 12 every 1 to 3 months may be warranted in some patients.
Calcium with vitamin D is an important supplement that is often overlooked in gastric bypass patients. Calcium absorption, which occurs in the duodenum, is bypassed by the procedure, placing these patients at increased risk for osteoporosis. Calcium citrate (1,200-1,500 mg/day along with 1,600 IU of vitamin D) is preferred over calcium carbonate. The pouch of gastric bypass patients contains fewer than the normal number of parietal cells, resulting in decreased acid secretion and accelerated absorption of calcium carbonate.
Deficiencies of these essential nutrients can cause significant neurologic and metabolic disorders; therefore, annual serologic testing and measurement of bone mineral density is recommended. In patients with significant steatohepatitis or fibrosis at the time of surgery, a liver biopsy performed 12 to 24 months postoperatively will help assess progression or regression of disease. Similarly, follow-up polysomnogram should be considered to ensure resolution of obstructive sleep apnea.
The ramifications of altered gut absorption for drug dosing extend well beyond the early postopera- 
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tive period. Adequate absorption of medication should be held in question at least until the jejunum has fully adapted surgical alterations. Measurement of blood drug levels may be necessary, particularly in patients receiving antiseizure, thyroid replacement, or antipsychotic medications, and dosages adjusted to achieve required therapeutic levels. In some cases, placement of a G-tube at the time of surgery is warranted to ensure adequate drug levels.
Pregnancy should be avoided for 12 to 18 months after surgery. The altered absorption of essential nutrients and rapid weight loss confer an increased risk for neural tube defects and other perinatal complications. 19, 20 As with all medications, therapeutic blood levels of oral birth control pills cannot be assumed and additional birth control (eg, barrier methods, patches, or intramuscular injection) is necessary.
Realistic expectations
Weight loss after bariatric surgery ranges from 30% to 90% of excess body-weight loss depending on the procedure performed. Even more important is amelioration of obesity-related comorbidities. A comprehensive meta-analysis by Buchwald et al showed that HbA 1c reverted to normal in 77% of patients with preoperative diabetes, blood pressure decreased to normal in 62% of patients, and obstructive sleep apnea resolved in 86%. 21 A more detailed discussion of this study can be found on page 15.
In a survey of 100 gastric bypass patients, some of whom had been followed for 20 years, Cook and Edwards found that patients with the most successful outcomes adhered to a strict regimen. The regimen included eating 5 small meals a day to avoid hunger, avoiding fluids for the first hour after eating, a daily intake of 60 oz of noncarbonated calorie-free beverages supplemented with calcium and vitamin B 12 , sleeping an average of 7 hours a night, exercising 2.5 hours a week, and weighing themselves at least once a week.
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Summary
Bariatric surgery can be a major effective component of comprehensive team management of morbid obesity, provided that the family physician gives serious consideration to both the bariatric program and surgical procedure. The family physician can be an integral member of the bariatric team who initiates patient selection, makes a referral to a program that includes medical, nutritional, psychologic, and surgical interventions, and participates in pre-and postoperative management. s
